



## Biographies

- [Dr Maddalena LETTINO, Italy](#)
- [Prof. Julia MASCHERBAUER, Austria](#)
- [Dr Matias NORDABY, Germany](#)
- [Dr André ZIEGLER, Switzerland](#)
- [Dr Isabelle RICHARD-LORDEREAU, Switzerland](#)
- [Prof. Frank VISSEREN, The Netherlands](#)
- [Assoc. Prof. Deirdre E. O'NEILL, Canada](#)
- [Dr Kristina DUNDER, Sweden](#)
- [Prof. Geneviève DERUMEAUX, France](#)
- [Prof. Stefan HOHNLOSER, Germany](#)
- [Prof. Jean-Philippe COLLET, France](#)
- [Prof. Herbert WATZKE, Austria](#)



**Dr Maddalena LETTINO**

Dr Maddalena Lettino is Director of the Clinical Cardiology Department at San Gerardo Hospital of Monza, Monza, Italy since 2019. Her previous appointment was Clinical Director for strategic development – Cardiology Clinical Lead, project management group for diagnosis & treatment of chronic cardiovascular diseases at Humanitas Research Hospital, Milan, Italy. She is also chairperson of the IEC of Milano Area 3.

After graduating in 1982 she developed her practice in research hospitals in Pavia and Milan. Dr Lettino has been a lecturer/adjunct professor at the Universities of Milan and Pavia since 1997. She has been chairperson of the Italian National Working Group of acute Cardiac Care, in charge of co-ordination of all the regional cardiologic initiatives and promotion of education and training in the sector. Nationally, this work concentrated on the management of the cardiologic emergency.

Dr Lettino has been also Past President of the ESC Acute Cardiac Care Association, and Chair of the Cardiovascular Heart Health Institute of the ESC in Brussels (2019-2020). She is currently member of the the Cardiovascular Round Table of the ESC. Finally, she is an editorial board member of the *European Heart Journal: Acute Cardiovascular Care* and of the *European Heart Journal of Cardiovascular Pharmacotherapy*. Dr Lettino's clinical research work is concentrated on antithrombotic therapy of acute coronary syndromes, physiopathological mechanisms of coronary atherothrombosis, and anticoagulation in thromboembolic disorders such as atrial fibrillation.



**Prof. Julia MASCHERBAUER**

## **Current position at the Medical University of Vienna (MUV), Department of Internal Medicine II, Division of Cardiology**

- Associate Professor of Cardiology
- Managing senior physician
- Head of the structural heart team
- Interventional cardiologist, structural heart disease specialist (TAVR, MitraClip, TriClip),
- Director, cardiac magnetic resonance imaging laboratory,
- Critical care medicine specialist.

## **Current positions in the European Society of Cardiology (ESC)**

- ESC Board 2018-2020
- Councillor, Young Community and Women in ESC 2018-2020
- Nucleus -Cardiovascular Round Table 2018-2020
- Council Board -Council on Valvular Heart Disease 2018-2020
- EACVI -Advocacy -Industry Round Table Committee 2018-2020
- ESC Membership Committee 2018-2020
- Official ESC spokesperson for ESC Congress and ongoing press activities
- Fellow of the ESC

## **Current activities in the National Cardiac Society and the Austrian Medical Chamber**

- National director of training for the ESC
- Since 2016 Commissioner, Cardiology specialist examination by the Austrian Medical Chamber
- Austrian Society of Cardiology, nucleus member of the working groups on
  - \* Interventional cardiology
  - \* Cardiac magnetic resonance imaging, cardiac computed tomography, and cardiac nuclear imaging
  - \* Pulmonary circulation and right ventricular function

## **Previous positions in the National Cardiac Society**

- 2014-2018: Board member
- 2014-2018: Coordinator, working groups of the Austrian Society of Cardiology
- 2014-2015: National guideline coordinator for the ESC
- 2014-2018: Scientific congress program coordinator, annual meeting of the Austrian Society of Cardiology
- 2012-2016: Director, working group “Cardiac magnetic resonance imaging, cardiac computed tomography, and cardiac nuclear imaging” of the Austrian Society of Cardiology



**Dr Matias NORDABY,  
Boehringer Ingelheim**

Working in industry for more than 10 years in a series of positions within Clinical Operations, Clinical Development and Medical Affairs. After several years as a cardiologist, focused on heart failure patient care, joined Boehringer Ingelheim in 2008 to manage the ongoing clinical trials in the anticoagulation and cardiometabolic space.

Later transitioned to the Corporate Medical Affairs Department working in multiple roles with increasing responsibility in the anticoagulation space and in the cardio-renal-metabolic space. Currently he is the Global Head of Medical Affairs for Heart Failure.



**Dr André ZIEGLER,  
Roche Diagnostics**

André Ziegler assumed the role of Global Clinical Leader for all cardiovascular diseases in Medical & Scientific Affairs (DXMA) in April 2019. In his current role, André is responsible to supervise all clinical studies to get global registrations of the cardiovascular products. In addition, he is leading the clinical research activities to discover and translate new biomarkers in various cardiovascular diseases, such as atrial fibrillation, coronary artery disease and heart failure.

André joined Roche in 2011 as Scientific Affairs Manager for cardiovascular diseases, and as Clinical Science Leader for cardiovascular diseases in 2015. In his various roles, André has helped Roche Diagnostics to increase the clinical research activities by leading the clinical evidence generation for several regulatory approval studies and new biomarker research in Cardiovascular Diseases prior to his current role to oversee all cardiovascular studies.

André studied Pharmacy at the Universities of Basel and Geneva (Switzerland), and he holds a Doctor of Natural Sciences from the Basel University studying the cardiac energy metabolism with Magnetic Resonance. He worked as a postdoctoral researcher at the Boston University Medical School and the Biozentrum (Institute of Molecular Sciences) at Basel University. André continued as Research Lead for Pharmaceutical Sciences in the Pharmazentrum (Institute of Pharmaceutical Sciences) at Basel University before starting his career in Roche.



**Dr Isabelle RICHARD-LORDEREAU,  
Amgen**

Isabelle Richard-Lordereau, MD is Executive Medical Director and Therapeutic Area Head of General Medicine Medical Affairs at AMGEN Europe, joining in 2018.

Prior to this role, Dr Richard-Lordereau spent 8 years at BMS as Europe Medical Lead to launch ELIQUIS (Apixaban) in various indications, building high-performing medical affairs teams and conducting several phase IV trials.

She dedicated 30 years in Cardiovascular and Thrombosis at Sanofi, Servier, GSK, BMS and Amgen. She served R&D as well as Medical Affairs and was given European as well as Global responsibilities. She has been involved in the launch and life cycle management strategies of several major antithrombotic drugs as well as design, execution and reporting of several phase III and phase IV clinical trials in atrial fibrillation, acute coronary syndromes, venous thrombosis and stroke.

Dr Richard-Lordereau is currently ESC CRT Industry Chair and has been elected in 2019 in this role.

Dr. Richard-Lordereau is originally trained in endocrinology, pediatric endocrinology and diabetes at APHP Hospitals in Paris, France (Cochin, Necker and Saint Vincent de Paul) where she was a resident and senior resident.

During her endocrinology fellowship, Dr. Richard Lordereau completed a master of immunology and molecular biology and spent 18 months of fundamental research in Mount Sinai hospital NY and INSERM Unit dedicated to Growth Hormones in Paris, France.



**Prof. Frank VISSEREN**

Prof. Frank Visseren (1965) is Professor of Medicine, Epidemiologist and Vascular Medicine specialist at the University Medical Center in Utrecht. He is head of the Department of Vascular Medicine and responsible for patient care, research, and teaching. His main research interest is in the field of (rare) lipid disorders, insulin resistance/DM2 and development of vascular complications, and in translating the results of large clinical trials and cohorts to individual patients, in collaboration with (inter)national partners.

He is (co-) author of >400 publications and supervised >40 thesis projects. He is the clinical director of the Second Manifestations of ARterial disease (SMART) cohort at the UMC Utrecht. This is a cohort started in 1996 with currently >14,000 patients with vascular diseases and/or type 2 diabetes or severe hypertension or familial hyperlipidemia, growing with 800 patients annually, for etiologic, prognostic, diagnostic and therapeutic research.

His research group has a track record in prediction research. The clinical work of the Department of Vascular Medicine is concentrated around patients at high risk for the development of (recurrent) cardiovascular diseases such as patients with genetic lipid disorders, therapy-resistant hypertension and patients with diabetes and vascular disease. He strongly believes in prevention in a multidisciplinary, patient-centered and tailored approach in the treatment of high risk for the development of (new) vascular diseases.

He was member of several National guideline committees and is now chair of the Task Force of the 2021 ESC CV Prevention Guidelines and steering committee member of the ESC Cardiovascular Risk Collaboration.



**Assoc. Prof. Deirdre E. O'NEILL**

Deirdre O'Neill is from Nova Scotia, Canada.

She completed her medical school, internal medicine residency and cardiology fellowships at the University of Alberta, in Edmonton, Alberta, as well as a Master of Science in translational medicine. Throughout her training, Deirdre became more aware of the nuanced care older adults require, sparking her interest in further training in care for the older adult. She also noticed a deficiency within the practice of cardiology in terms of providing appropriate palliative care. This led Deirdre to the University of Pittsburgh, in Pennsylvania, USA, where she completed a geriatric fellowship, with special training in palliative care. Deirdre has now returned to the University of Alberta Hospital, where she is an associate professor in the Department of Medicine, Division of Cardiology, practicing geriatric and palliative care cardiology.





**Dr Kristina DUNDER**

Dr Dunder graduated from Uppsala University (School of Medicine) in 1988. She specialized in internal medicine and endocrinology/diabetology and served as a medical doctor at the Uppsala Academic Hospital until 2005.

In 2004 she defended a thesis with the title "Clinical manifestations of coronary heart disease and the metabolic syndrome".

Since 2005 Dr Dunder holds a position as a senior expert at the Medical Product Agency in Uppsala, Sweden.

She is the Swedish member of CHMP (Committee of Human Medical Products) at the EMA (European Medicine Agency) and the chair of the cardiovascular working party.

Dr Dunder was the Rapporteur for the Question-and-Answer document to the ICH (International Conference of Harmonization) E7 guideline concerning studies in the geriatric population.



**Prof. Geneviève DERUMEAUX**

## **Education, positions and diploma**

Medical School: Université de la Timone , Marseille (1976-1983)

- Cardiology specialist training: Bordeaux University Hospital (1983-1988)
- Clinical research post in University Laval in Quebec (1985)
- Full-Staff, Assistant Professor, Department of Cardiology, Rouen (1988-1993)
- Professor of Medicine, Cardiologist, University of Rouen (2000)
- Professor of Medicine, Physiology, University of Lyon (2004)
- Associated Chief of the Department of Cardiology, Charles Nicolle Hospital, Rouen (2000)
- Head of the Department of Echocardiography: Lyon University Hospital (since 2004)
- Chief of the Heart Failure Department: Lyon University Hospital (since 2011)

## **Awards and distinctions**

- Silver medal European Society of Cardiology (ESC, 2016)
- Laennec lecture recipient (ESC, 2017)
- Award of the Honorary membership of European association of cardiovascular imaging (EACVI 2018)

## **Current position**

- Professor in Cardiology and Physiology, Faculté de Créteil, Paris Est University
- Member of IMRB Inserm U955, Team 8 (future director of team 10: Senescence, metabolism, and cardiovascular diseases, starting January 2020)
- Head of the Physiology Department and Functional Exploration Department, Henri Mondor University Hospital (APHP) in Créteil

## **Research career**

- Member of the research group INSERM E9920 (EMI) : Pharmacologie de l'adaptation endothéliale vasculaire et de la dysfonction cardiaque. Rouen University (1999-2003)
- Invited professor, Massachusetts General Hospital, Harvard Medical School, Boston (2003)
- Member of the research group "INSERM U886: Cardioprotection": Lyon University (2004)
- Member of the INSERM research group IMRB U955, UPEC University (since 2014)
- Head of INSERM research group IMRB team 10 on "Senescence, metabolism and cardiovascular diseases" (starting 2020)



## Research and university administrative positions

- Member of INSERM commission CSS3 since 2016
- Member of CNU of Physiology (Section 44-02) since 2014
- Member of APHP CRMBSP in 2015-16
- Member of Scientific Evaluation Board of the Norwegian Health Association since 2017
- Member of the Board of BAILLET LATOUR HEALTH PRIZE (FNRS) in 2018
- Member of the Scientific Evaluation Board of Fondation de France since 2018

## Position in scientific organizations

### European Society of Cardiology:

- Chair of the ESC Congress Program Committee (2014-2016)
- Vice-President of the ESC Board (2012-2014)
- Councilor of the ESC Board (2010-2012)
- Member of the ESC Congress Program Committee (2008-2012)
- Member of the Nucleus of the WG Pulmonary Circulation and Right Ventricular Function
- Secretary of the European Association of Cardiovascular Imaging (2002-2006)
- Member of the ESC Education Committee (2002-2004)
- Fellow of the European Society of Cardiology

### French Society of Cardiology:

- President of the French Society of Cardiology, (2010-2012)
- Scientific Secretary of the French Society of Cardiology (2004-2008)
- Treasurer of the French Society of Cardiology (2002-2004)

## Editorial activities

- Associate editor of European Heart journal Cardiovascular imaging (since 2015)
- Associate editor of Cardiology (since 2018)
- Member of the editorial board of Circulation (since 2017)

## Major Research Interests

- Quantification of myocardial function; cardiomyopathy
- Translational research in myocardial protection (imaging in murine models)
- Clinical applications of myocardial velocity imaging (ischemic cardiomyopathy, dyssynchrony , etc)
- Myocardial function and aging (Coordinator of RHU CARMMA)
- Metabolic cardiomyopathy (Coordinator of the French translational research network on Diabetic Cardiomyopathy under the auspices of ITMO Physiopathology/Nutrition/Metabolism)
- Cellular senescence and aging

## Experience in clinical and translational research

- Invited Professor in 2003 by Harvard Medical School (Boston, USA) to lead a translational research project assessing myocardial function in murine models of aging.
- As an expert in echocardiography, she has closely participated to the development of new devices (Transcatheter Aortic Valve Implantation [TAVI]) and is involved in major European registries (EORP)
- As Head of an imaging corelab, she is co-coordinator of multicenter national and international clinical trials [FOP-ASIA, STIC CLOSE 2006, REGULATE, cohort studies (CARIM, PREGICA).
- She contributed to more than 220 international publications (h index=56), reviews & international conferences.
- She filed 2 patents on myocardial aging prevention (PCT/EP2017/058159 and EP19186370.3).
- She has supervised 8 Master 2 students, 14 PhD students and 5 post-docs since 2004.



## Prof. Stefan HOHNLOSER

Prof. Hohnloser is a Professor emeritus of Medicine and Cardiology at the J. W. Goethe University in Frankfurt, Germany.

He also holds a position as a senior researcher at the center of thrombosis and hemostasis at the university of Mainz, Germany.

Dr. Hohnloser has served as the principal investigator or a member of the steering committee for many international large randomized clinical trials related to contemporary issues in clinical arrhythmology. He has co-authored over 455 publications in peer-reviewed journals, >500 abstracts and 50 book chapters.

Dr. Hohnloser has been or is currently serving on several committees of the European Society of Cardiology and the Heart Rhythm Society. His primary research interests focus on risk stratification for and prevention of sudden cardiac death, and pharmacological, antithrombotic, and interventional therapies of atrial fibrillation.



**Prof. Jean-Philippe COLLET**

Prof. Jean-Philippe Collet is a Professor of Cardiology at Pitié-Salpêtrière Hospital (APHP) where he leads the interventional catheterization unit (PCI and TAVI). He is also the director of Cardiovascular Training Program at Sorbonne Université.

His main expertise is in the field of thrombosis, the effect of antithrombotic agents and the development of new devices for structural heart intervention. He is a member and a founder of the Academic Research Organisation A.C.T.I.O.N (Alliés in Cardiovascular Trials, Initiatives and Organized Networks) ([www.action-coeur.org](http://www.action-coeur.org)).

He has led clinical trials as a principal investigator (AMERICA, DOSAPI, ARCTIC and ATLANTIS). He has several commitments in the ESC. He is a Fellow of the European Society of Cardiology, a member of the nucleus of the WG Thrombosis and a member of the Clinical Practice Guidelines Committee.

He has served as the Chair of the EAPCI scientific program for two years and is now co-chairing the upcoming guidelines on NSTEMI-ACS.



**Prof. Herbert WATZKE**

## **Academic Career**

Head of the Department of Internal Medicine I, Medical University of Vienna (since 2017)

Chief, Division of Palliative Medicine, Medical University of Vienna (since 2005)

Board Certification for Internal Medicine, Cardiology and Hematology/Oncology

Chairmen, Austrian Society of Palliative Medicine (2008-12)